Overview and Scope
The hyperimmune globulins market consists of sales of bayrab, hepaGam B, Tetanus Immune Globulin (TIG), variZIG, respiGam, and cytogam. Values in this market are ‘factory gate’ values, that is, the value of gooHyperlocal Delivery App Market
ds sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Sizing and Forecast
The hyperImmune globulins market size has grown strongly in recent years. It will grow from $1.78 billion in 2023 to $1.91 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increased government support, rise in healthcare expenditures., high prevalence of hepatitis b and rabies, rise in awareness of zoonotic diseases, and growth in the geriatric population.
The hyperImmune globulins market size is expected to see strong growth in the next few years. It will grow to $2.57 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to the increasing prevalence of infectious diseases, growing awareness about the benefits of hyperimmune globulin injections, increasing demand for immunoglobulins, rising prevalence of alpha-1 antitrypsin deficiency, rising incidence of immune deficiencies. Major trends in the forecast period include technological advancements and innovation, investment in research and development, demand for passive immunity treatments, advancements in plasma-derived therapies, and technological advancements in manufacturing.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/hyperimmune-globulins-global-market-report
Segmentation & Regional Insights
The hyperimmune globulins market covered in this report is segmented –
1) By Type: Hepatitis B Hyperimmune Globulin, Rabies Hyperimmune Globulin, Tetanus Hyperimmune Globulin, Cytomegalovirus (CMV) Hyperimmune Globulin, Varicella-Zoster Virus (VZV) Hyperimmune Globulin, Respiratory Syncytial Virus (RSV) Hyperimmune Globulin, Other Types
2) By Route Of Administration: Intramuscular, Intravenous
3) By Application: Government Institution, Private Sector, Other Applications
North America was the largest region in the hyperimmune globulins market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperimmune globulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16448&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of infectious diseases is expected to propel the growth of the hyperimmune globulin market going forward. Infectious diseases are illnesses caused by harmful agents (pathogens) that get into your body, such as viruses, bacteria, fungi, and parasites. The increasing prevalence of infectious diseases can be attributed to factors such as antimicrobial resistance, climate change, and population growth. Hyperimmune globulins are utilized in infectious diseases to provide immediate passive immunity by delivering concentrated antibodies against specific pathogens, aiding in the prevention or treatment of diseases such as rabies, hepatitis B, or tetanus. For instance, in April 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, chronic hepatitis B cases in the US increased by approximately 17% from 14,229 cases in 2021 to 16,729 cases in 2022. Therefore, the increasing prevalence of infectious diseases is driving the growth of the hyperimmune globulin market.
<h4 class=reporthtag>Government-Led Healthcare Research And Development Initiatives A Boost For HyperImmune Globulins</h4>
Government initiatives for research and development in healthcare are expected to propel the growth of the hyperimmune globulins market going forward. Government initiatives for research and development in healthcare are rising due to increasing demand for innovative medical solutions and the need to address emerging health challenges. Government initiatives facilitate the development and accessibility of hyperimmune globulins to combat specific infectious diseases effectively. For instance, in 2022, according to the Department of Health and Social Care, a UK-based government authority, the UK government announced £260 million (US $270.65) million in funding to boost healthcare research and manufacturing. This was committed by Business, Energy, and Industrial Strategy (BEIS) and the Department of Health and Social Care (DHSC) to support NHS-led health research into diagnostics and treatment through new privacy-preserving platforms and clinical research services, and £60 million (US $63.60 million) to help expand life sciences manufacturing in the UK. Therefore, the increasing government initiatives for research and development in healthcare drive the hyperimmune globulins market.
Key Industry Players
Major companies operating in the hyperimmune globulins market are F. Hoffmann-La Roche AG, Bayer AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Ltd., Fresenius Kabi AG, Grifols SA, Octapharma AG, Shanghai RAAS Blood Products Co. Ltd., Emergent BioSolutions Inc., Kedrion Biopharma Inc., LFB SA, Hualan Biological Engineering Inc., FFF Enterprises Inc., Taibang Biologic Group, Bio Products Laboratory (BPL) Ltd., ADMA Biologics, Cangene Corporation, Kamada Ltd., Saol Therapeutics Inc., Omrix Biopharmaceuticals Ltd., Shire, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., BioCare Inc.
The hyperimmune globulins market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
